Lupin collaborates with Fuji Pharma arm for marketing birth control pill Nextstellis in Vietnam, Philippines

Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.

“We are delighted to collaborate with Fuji and OLIC to offer Nextstellis to our patients in Vietnam and the Philippines. This new addition to our Women’s Health portfolio will strengthen our commitment to expand healthcare options worldwide,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

Fuji is a Tokyo Stock Exchange (TSE) listed, Japan‐based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Fuji focuses on the field of women’s health care with a wide variety of new and generic drugs for women’s specific diseases such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders.

Read also: Lupin bags USFDA tentative nod for Letermovir Tablets

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Read also: Lupin gets ISO 14001 and ISO 45001 certification across all its Indian manufacturing sites, RnD Center, Corporate Office

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin buys two brands from Sanofi in Europe, Canada